*TLF is defined as a composite of Cardiac Death, TV-MI, emergent Coronary Artery Bypass Grafting (eCABG), and CD-TLR. Peri-procedural MI according to SCAI definition and spontaneous MI according to the extended historical definition; **0.4% of cases without early antiplatelet or anticoagulant interruption at post procedure; § 0.5% scaffold thrombosis rate excluding cases with early antiplatelet or anticoagulant interruption. All events have been adjudicated by an independent clinical event committee. BIOSOLVE-IV data based on Kaplan-Meier failure estimate analysis including censored observations.
1. Joner M, Ruppelt P, Zumstein P, et al. Preclinical Evaluation of Degradation Kinetics and Elemental Mapping of First and Second Generation Bioresorbable Magnesium Scaffolds. EuroIntervention. 2018 Feb 20. pii: EIJ-D-17-00708. doi: 10.4244/EIJ-D-17-00708; 2. Haude M, Ince H, Kische S, et al. Safety and clinical performance of a drug eluting absorbable metal scaffold in the treatment of subjects with de novo lesions in native coronary arteries: Pooled 12-month outcomes of BIOSOLVE-II and BIOSOLVE-III. Catheter Cardiovasc Interv. 2018;00:1–10. doi: 10.1002/ccd.27680; 3. Haude M, Ince H, Kische S, et al. Sustained safety and performance of the second-generation sirolimus-eluting absorbable metal scaffold: Pooled outcomes of the BIOSOLVE-II and -III trials at 3 years. Cardiovascular Revascularization Medicine. 2020. doi: 10.1016/j.carrev.2020.04.006; 4. Dangas G, Serruys P, Kereiakes D, et al. Meta-Analysis of Everolimus-Eluting Versus Paclitaxel-Eluting Stents in Coronary Artery Disease. Final 3-Year Results of the SPIRIT Clinical Trials Program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC: Cardiovascular Interventions. 2013; 6/9; doi: 10.1016/j.jcin.2013.05.005; 5. EVOLVE FHU 24m: Meredith I, Verheye S, Weissmann N, et al. Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent. EuroIntervention. 2013; 9: 308-315 and Meredith I, Verheye S, Dubois C et al. Final five-year clinical outcomes in the EVOLVE trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent. EuroIntervention 2018;13:2047-2050. doi: 10.4244/EIJ-D-17-00529; 6. BIOTRONIK data on file; 7. Schmidt W, Behrens P, Brandt-Wunderlich C, et al. In vitro performance investigation of bioresorbable scaffolds - Standard tests for vascular stents and beyond. Cardiovasc Revasc Med. 2016;17(6):375-83. doi: 10.1016/j.carrev.2016.05.001; 8. Hideo-Kajita A, Garcia-Garcia HM , Kolm P, et al. Comparison of clinical outcomes between Magmaris and Orsiro drug eluting stent at 12 months: Pooled patient level analysis from BIOSOLVE II–III and BIOFLOW II trials. International Journal of Cardiology. 2019: 1-30. doi: 10.1016/j.ijcard.2019.11.003; 9. BIOSOLVE-II case, GER443-012. Courtesy of M. Haude, Lukaskrankenhaus Neuss, Germany 2015; 10. Lipinski MJ, Acampado E, Cheng Q, et al.Comparison of Acute Thrombogenicity for Magnesium versus Stainless Steel Stents in a Porcine Arteriovenous Shunt Model. EuroIntervention. 2018 May 8. pii: EIJ-D-17-00958. doi: 10.4244/EIJ-D-17-00958; 11. Nakazawa G, Vorpahl M, Finn M, et al. One Step Forward and Two Steps Back With Drug-Eluting-Stents. JACC: Cardiovascular Imaging . 2009; 2(5): 625-628. doi: 10.1016/j.jcmg.2009.01.011; 12. Joner M. Systemic vs Site Targeted Treatment of Neoatherosclerosis. Presented at: ESC; Aug 28, 2017; Barcelona, Spain; 13. Andreou I, Stone P. In-Stent Atherosclerosis at a Crossroads. Neoatherosclerosis … or Paleoatherosclerosis? Circulation. 2016;134:1413–1415. doi: 10.1161/CIRCULATIONAHA.116.025129; 14. Bennett J. Performance and safety of the resorbable magnesium scaffold, Magmaris in a real-world setting – Primary and secondary endpoint analysis of the full cohort (2,066 subjects) of the BIOSOLVE-IV, Presented at: TCT 2021, November 2021, Orlando, USA. ClinicalTrials.gov: NCT02817802; 15. Torzewski J. Safety and performance of Magmaris at 36-months: BIOSOLVE-IV first cohort. Presented at: EuroPCR; 2022; ClinicalTrials.gov: NCT02817802; 16. Haude M, Toelg R , Lemos P.A et al. Sustained safety and performance of a second-generation sirolimus-eluting absorbable metal scaffold: Long-term data of the BIOSOLVE-II first-in-man trial at 5 years. Cardiovascular Revascularization Medicine. 2021. doi: 10.1016/j.carrev.2021.07.017; 16. Haude M, Toelg R , Lemos P.A et al. Sustained safety and performance of a second-generation sirolimus-eluting absorbable metal scaffold: Long-term data of the BIOSOLVE-II first-in-man trial at 5 years. Cardiovascular Revascularization Medicine. 2021. doi: 10.1016/j.carrev.2021.07.017; 17. Joner M. Magmaris: Reducing the risk of neoatherosclerosis. Presented at: TCT; Sep 22, 2018; San Diego, USA.
BIOSOLVE- II and -IV based on Kaplan-Meier failure estimate analysis including censored observations. The pooled analysis of BIOSOLVE-II and -III based on frequency analysis.
Magmaris is a trademark or registered trademark of the BIOTRONIK Group of Companies. Xience is a trademark or registered trademark of the Abbott Group of Companies. Synergy is a trademark or a registered trademark of the Boston Scientific Group of Companies.
Magmaris is currently not available in the US.
© 2022 BIOTRONIK AG – All rights reserved.
Specifications are subject to modification, revision and improvement.